 Home > Active Ingredient News > Drugs Articles > Takeda reached a collaboration with US$303 million to help develop liposome-delivered gene therapy

Takeda reached a collaboration with US$303 million to help develop liposome-delivered gene therapy

 Last Update: 2021-09-13
 Source: Internet
 Author: User

Tags

liver extract

diet related diseases

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On August 23, 2021, Genevant Sciences and Takeda announced that they have reached a global cooperation and licensing agreement to use Genevant’s proprietary lipid nanoparticle (LNP) technology platform to develop new non-viral vector gene therapy and treatment Rare liver disease
.

This is the second collaboration between Genevant and Takeda.

Under the terms of the agreement, Genevant will be eligible to receive up to US$303 million in advance and potential milestone payments, and royalties for future product sales
.

Takeda will have the exclusive rights to use Genevant's LNP technology platform to develop and commercialize designated non-viral vector gene therapies to treat rare liver diseases for which information has not yet been disclosed

Genevant's LNP technology platform has been studied in more than ten product candidates, and its safety and effectiveness have been evaluated in multiple clinical projects with more than 600 subjects
.

The company's LNP technology was used to deliver the approved RNAi therapy patisiran

Reference materials:

[1] Genevant Sciences Announces Global Collaboration and License Agreement with Takeda to Develop Novel Nonviral Gene Therapies for Up to Two Rare Liver Diseases.

[1] Genevant Sciences Announces Global Collaboration and License Agreement with Takeda to Develop Novel Nonviral Gene Therapies for Up to Two Rare Liver Diseases.
August 23 2021.
from https:// Genevant-Sciences-Announces-Global-Collaboration-and-License-Agreement-with-Takeda-to-Develop-Novel-Nonviral-Gene-Therapies-for-Up-to-Two-Rare-Liver-Diseases

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Top Product

$49-62/KG FOB

Safe Delivery Freeze Dried Peptides Raw Powder Weight Loss Tirze Peptide Sema 5mg 10mg

CAS No.: 2023788-19-2

Pharmacy Grade

$120.00/UNIT FOB

Hot Sale 1-Adamantanamine Hydrochloride /1-Adamantanamine HCl CAS 665-66-7

CAS No.: 665-66-7

Pharmacy Grade

$20-25/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.